Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vasculitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    110 result(s) found for: Vasculitis. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2006-001663-33 Sponsor Protocol Number: MYCYC Start Date*: 2007-12-06
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A randomised clinical trial of mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA associated vasculitis
    Medical condition: Anti neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) DE (Completed) IT (Completed) AT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001222-15 Sponsor Protocol Number: CL002_168 Start Date*: 2011-07-20
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis on Bac...
    Medical condition: Non-life-threatening anti-neutrophil cytoplasmic antibody vasculitis (AAV) with mild-to-moderate renal involvement
    Disease: Version SOC Term Classification Code Term Level
    18.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) CZ (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) PL (Completed) AT (Completed) IE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004519-29 Sponsor Protocol Number: APHP180351 Start Date*: 2021-03-18
    Sponsor Name:Assistance Publique - Hôpitaux de Paris / DRCI
    Full Title: Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active cryoglobulinemia vasculitis compared to placebo TRIBECA STUDY (Tr...
    Medical condition: Adult patients with non-infectious active cryoglobulinemia vasculitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10075624 Cryoglobulinaemic vasculitis LLT
    21.0 100000004866 10075623 Cryoglobulinemic vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003964-30 Sponsor Protocol Number: BIOVAS Start Date*: 2020-10-22
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vascu...
    Medical condition: Non-ANCA associated vasculitides: 1. Giant cell arteritis (GCA) 2. Takayasu’s arteritis (TA) 3. Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN) 4. Relapsing p...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2009-017087-17 Sponsor Protocol Number: AL1.0 Start Date*: 2010-09-29
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Alemtuzumab for ANCA-Associated Refractory Vasculitis - A study of safety and efficacy (ALEVIATE).
    Medical condition: ANCA-associated vasculitis (AAV)
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001970-28 Sponsor Protocol Number: CMV-001 Start Date*: 2012-11-20
    Sponsor Name:University of Birmingham
    Full Title: Does CMV reactivation cause functional impairment of CMV specific CD4+ T-cells? The potential for valaciclovir to prevent CMV-mediated adverse modulation of the immune system in patients with ANCA-...
    Medical condition: This study will investigate the modulation of the immune system by Cytomegalovirus (CMV) in ANCA-associated vasculitis. Specifically the study will investigate the potential for valaciclovir to ...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2025-000001-16 Sponsor Protocol Number: I4V-JE-JAJE Start Date*: 2025-02-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2/3, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Baricitinib in Adult and Pediatric Japanese Patients with NNS/CANDLE, SAVI, and AGS
    Medical condition: Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy with Onset in Infancy, Aicardi Goutieres Sy...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10073960 CANDLE syndrome PT
    21.1 10047065 - Vascular disorders 10047115 Vasculitis PT
    27.1 10010331 - Congenital, familial and genetic disorders 10054935 Aicardi's syndrome PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2009-013220-24 Sponsor Protocol Number: Start Date*: 2009-11-02
    Sponsor Name:Addenbrooke's Hospital
    Full Title: Plasma Exchange and Glucocorticoid Dosing in the Treatment of Anti-neutrophil Cytoplasm Antibody Associated Vasculitis: an International Randomised Controlled Trial
    Medical condition: ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001245-41 Sponsor Protocol Number: 2005/Diaminodiphenylsulfon/1 Start Date*: 2005-09-23
    Sponsor Name:Department of Dermatology, Hospital of the Medical University Graz
    Full Title: A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis
    Medical condition: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease and is manifested clinically by a spectrum of cutaneous lesions, although “papable purpura” is its clinical hallmark. The p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001859-35 Sponsor Protocol Number: cro632 Start Date*: 2007-04-13
    Sponsor Name:Imperial College London
    Full Title: Abatacept in ANCA associated vasculitis: ABAVAS
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002114-13 Sponsor Protocol Number: P170910J Start Date*: 2019-05-24
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Efficacy of Colchicine to prevent skin relapses in adult's IgA vasculitis
    Medical condition: Immunoglobulin A vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10047121 Vasculitis Henoch-Schonlein like LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001215-69 Sponsor Protocol Number: 69HCL17_0020 Start Date*: 2018-09-24
    Sponsor Name:Hospices Civils de Lyon
    Full Title: MAINEPSAN Study A Prospective Comparative Randomized Double-blind Placebo-controlled In-Parallel Groups Multicenter, Study to Evaluate the remission MAINtenance using Extended administration of ...
    Medical condition: Patients with newly diagnosed or relapsing granulomatosis with polyangiitis (GPA, Wegener’s) or microscopic polyangiitis (MPA) , 12 months after initiation of treatment for vasculitis onset or flar...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002068-29 Sponsor Protocol Number: ANCA_CGM Start Date*: 2019-10-24
    Sponsor Name:Medizinische Universität Graz, Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie
    Full Title: Influence of once vs twice daily corticosteroid administration on glycemia assessed by continuous glucose monitoring in patients with ANCA vasculitis
    Medical condition: ANCA vasculitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-001102-14 Sponsor Protocol Number: Ritazarem Start Date*: Information not available in EudraCT
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis
    Medical condition: ANCA vasculitis.
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10047889 Wegeners granulomatosis LLT
    15.0 10047065 - Vascular disorders 10047888 Wegener's granulomatosis PT
    15.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    15.0 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) SE (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003563-36 Sponsor Protocol Number: ACQUIVAS Start Date*: 2018-07-30
    Sponsor Name:Cambridge University Hospital NHS Foundation Trust and University of Cambridge
    Full Title: ACQUIVAS - Acquired immunodeficiency in ANCA associated vasculitis (AAV)
    Medical condition: Pneumococcal vaccine responses in ANCA associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-000637-12 Sponsor Protocol Number: P170909J Start Date*: 2019-03-29
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Efficacy and safety of rituximab in the treatment of good prognosis microscopic polyangiitis
    Medical condition: Patients with newly diagnosed or relapsing MPA, without any poor prognosis marker (FFS=0). Stratification will be made according to peripheral nerve involvement.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020063-21 Sponsor Protocol Number: ILUVIT1 Start Date*: 2010-06-15
    Sponsor Name:Charité-Universitätsmedizin
    Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”
    Medical condition: Urticarial vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048820 Urticarial vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000390-37 Sponsor Protocol Number: CHD005-17 Start Date*: 2017-12-01
    Sponsor Name:Centre Hospitalier Départemental Vendée de la Roche sur Yon
    Full Title: Maintaining or Stopping immunosuppressive Therapy in patients with ANCA vasculitis and End-stage Renal disease: a prospective, multicenter, randomized, open-label, clinical trial
    Medical condition: End-stage renal disease ANCA vascularitis Immunosuppressive therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001121-14 Sponsor Protocol Number: CL010_168 Start Date*: Information not available in EudraCT
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculi...
    Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10072579 Granulomatosis with polyangiitis PT
    20.0 10047065 - Vascular disorders 10063344 Microscopic polyangiitis PT
    20.1 10021428 - Immune system disorders 10050894 Anti-neutrophil cytoplasmic antibody positive vasculitis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) SE (Completed) DE (Completed) GB (Completed) AT (Completed) CZ (Completed) NL (Completed) ES (Completed) HU (Completed) DK (Completed) BE (Completed) NO (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000275-25 Sponsor Protocol Number: P140915 Start Date*: 2016-03-21
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiit...
    Medical condition: Patients with a diagnosis of EGPA with newly-diagnosed disease or with a relapsing disease at the time of screening
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10048594 Allergic granulomatous angiitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 08:37:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA